Fred Alger Management Inc. lifted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 9.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 400,722 shares of the biopharmaceutical company’s stock after buying an additional 35,328 shares during the quarter. Fred Alger Management Inc. owned approximately 0.28% of Halozyme Therapeutics worth $8,119,000 as of its most recent SEC filing.
Other large investors have also added to or reduced their stakes in the company. 361 Capital LLC purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth about $207,000. Trexquant Investment LP purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth about $224,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth about $227,000. Great West Life Assurance Co. Can boosted its stake in Halozyme Therapeutics by 44.1% in the 3rd quarter. Great West Life Assurance Co. Can now owns 14,291 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 4,371 shares in the last quarter. Finally, Marcus Capital LLC bought a new position in Halozyme Therapeutics in the 4th quarter worth about $298,000. 85.68% of the stock is currently owned by hedge funds and other institutional investors.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) opened at $20.61 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 3.85 and a current ratio of 3.89. The stock has a market cap of $2,949.52, a PE ratio of 54.25 and a beta of 1.87. Halozyme Therapeutics, Inc. has a one year low of $11.41 and a one year high of $21.13.
A number of equities analysts recently issued reports on the stock. Deutsche Bank set a $21.00 price target on shares of Halozyme Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 24th. Canaccord Genuity upped their price target on shares of Halozyme Therapeutics from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, February 21st. BidaskClub upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, December 12th. BMO Capital Markets reiterated a “market perform” rating and issued a $19.00 price target (up previously from $18.00) on shares of Halozyme Therapeutics in a research note on Thursday, February 22nd. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $22.00 price target (up previously from $19.00) on shares of Halozyme Therapeutics in a research note on Wednesday, February 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $19.89.
TRADEMARK VIOLATION NOTICE: “Fred Alger Management Inc. Acquires 35,328 Shares of Halozyme Therapeutics, Inc. (HALO)” was published by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/03/12/fred-alger-management-inc-acquires-35328-shares-of-halozyme-therapeutics-inc-halo.html.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.
Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO).
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.